Leerink lowered the firm’s price target on Thermo Fisher (TMO) to $600 from $625 given lower peer multiples, while keeping an Outperform rating on the shares. The firm notes the company reported ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...